세계의 면역글로불린 A(IgA) 혈관염 시장 보고서(2025년)

Immunoglobulin A IgA Vasculitis Global Market Report 2025

US $ 4,490 ￦ 6,498,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,393,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,288,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

면역글로불린 A(IgA) 혈관염 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 성장은 첨단 바이오마커의 사용 증가, 동반 질환의 발병률 증가, 임상 시험의 증가, 생물학적 치료에 대한 관심 고조, 최소 침습 치료 옵션에 대한 수요 확대에 기인할 수 있습니다. 주요 동향으로는 정밀 의학의 통합, 면역 억제 요법의 혁신, 질병 수정 치료의 개발, 조기 진단을 위한 바이오마커의 발전, 치료 계획에 인공 지능의 통합 등이 있습니다.

자가면역 질환의 발병률이 증가함에 따라 면역 글로불린 A(IgA) 혈관염 시장이 성장할 것으로 예상됩니다. 자가면역 질환은 면역 체계가 감염으로부터 몸을 방어하는 대신 자신의 건강한 세포, 조직, 또는 장기를 공격할 때 발생합니다. 이러한 질환의 유병률 증가의 주요 원인은 환경 오염물질에의 노출 증가로, 이는 면역 조절을 방해하고 비정상적인 면역 반응을 유발할 수 있습니다. IgA 혈관염은 작은 혈관에서 염증을 유발함으로써 자가면역 질환에 역할을 하며, 다양한 자가면역 질환의 이해와 치료에 도움을 줄 수 있는 통찰을 제공합니다. 예를 들어(2024년) 11월 독일 기반 기관인 Versorgungsatlas.de의 데이터에 따르면 2022년 보험 가입자 7,324만 1,305명 중 630만 4,340명이 최소 한 가지 자가면역 질환으로 진단받았으며, 이는 원시 유병률 8.61%에 해당합니다. 따라서 이 증가하는 발생률은 IgA 혈관염 시장 성장을 촉진하고 있습니다.

표적 치료에 대한 관심이 높아짐에 따라 면역 글로불린 A(IgA) 혈관염 시장의 성장이 촉진될 것으로 예상됩니다. 표적 치료는 질병과 관련된 분자 이상을 특이적으로 억제하여 치료의 정확성을 높이고 건강한 세포에 대한 손상을 최소화하기 위해 고안된 치료법입니다. 표적 치료에 대한 관심이 높아지는 것은 주로 정밀 의학의 발전에 기인합니다. 정밀 의학은 개인의 유전적 특성에 따라 치료법을 맞춤화하여 치료 효과를 높입니다. IgA 혈관염에서 표적 치료법은 특정 면역 경로를 표적으로 삼아 전신 부작용을 줄이고 염증을 완화하며 장기 손상을 예방함으로써 환자의 치료 결과와 삶의 질을 향상시킵니다. 예를 들어(2024년) 12월 미국 유전자 및 세포 치료학회(ASGCT)는 2023년에 FDA가 6개의 유전자 치료 제품을 승인했다고 보고했으며, 이는 2022년의 5개 승인에서 증가한 수치로, 표적 치료법 분야의 혁신이 가속화되고 있음을 반영합니다. 따라서 표적 치료에 대한 관심이 높아짐에 따라 면역 글로불린 A 혈관염 시장이 발전하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 전신성 면역글로불린 A(IgA) 혈관염 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 면역글로불린 A(IgA) 혈관염 시장의 성장률 분석
• 세계의 면역글로불린 A(IgA) 혈관염 시장 규모 실적과 성장(2019-2024년)
• 세계의 면역글로불린 A(IgA) 혈관염 시장 규모와 성장 예측(2024-2029년, 2034년)
• 전신성 면역글로불린 A(IgA) 혈관염 : 총 잠재 시장 규모(TAM)

제6장 시장 세분화

• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 치료 유형별, 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 의약품
• 혈장 교환
• 지지 요법
• 면역억제요법
• 면역글로불린 A(IgA) 혈관염 세계 시장 : 진단 방법별, 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 혈액 검사
• 소변 검사
• 이미지 연구
• 생검
• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 투여 경로별, 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 주사제
• 정맥내
• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 최종 사용자별, 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 전문 클리닉
• 재택 케어
• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 의약품 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 코르티코스테로이드
• 면역억제제
• 시클로포스파미드
• 아자티오프린
• 미코페놀산모페틸
• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 혈장 교환 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 치료적 혈장 교환
• 플라즈마 여과
• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 지지 요법 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 통증 관리
• 신장 기능 지원
• 혈압 관리
• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 면역억제요법 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 메토트렉세이트
• 리툭시맙
• 시클로포스파미드

제7장 지역 및 국가별 분석

• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 지역별, 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 면역글로불린 A(IgA) 혈관염 시장 : 국가별, 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 면역글로불린 A(IgA) 혈관염 시장 경쟁 구도
• 면역글로불린 A(IgA) 혈관염 시장에서의 기업 프로파일
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

제31장 기타 주요 기업 및 혁신 기업

• Amgen Inc.
• Indraprastha Medical Corporation Limited
• Intas Pharmaceuticals Ltd
• Mayo Clinic
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• The Cleveland Clinic Foundation
• Zydus Lifesciences Limited
• CSL Behring
• Artemis Medicare Services Limited
• Biocad BIoTechnology Company
• BIoTest AG
• Kauvery Hospitals Private Limited
• Sheikh Shakhbout Medical City
• Reliance Life Sciences Pvt. Ltd

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 면역글로불린 A(IgA) 혈관염 시장(2029년) : 가장 새로운 기회를 제공하는 국가
• 면역글로불린 A(IgA) 혈관염 시장(2029년) : 가장 새로운 기회를 제공하는 부문
• 면역글로불린 A(IgA) 혈관염 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Immunoglobulin A (IgA) vasculitis is an autoimmune disorder marked by inflammation of small blood vessels caused by deposits of IgA antibodies. It primarily affects the skin, joints, kidneys, and gastrointestinal tract, manifesting as purplish rashes, abdominal pain, and joint inflammation.

The main treatment approaches for IgA vasculitis include medications, plasma exchange, supportive care, and immunosuppressive therapy. Medications are mainly aimed at reducing inflammation and managing symptoms such as joint pain, skin rash, and kidney issues resulting from immune reactions triggered by IgA deposits. Diagnosis typically involves blood tests, urinalysis, imaging, and tissue biopsy. Treatments are administered via oral, injectable, or intravenous routes and are provided in hospitals, specialty clinics, and homecare settings.

The immunoglobulin A (IgA) vasculitis market research report is one of a series of new reports from The Business Research Company that provides immunoglobulin A (IgA) vasculitis market statistics, including the immunoglobulin A (IgA) vasculitis industry's global market size, regional shares, competitors with the immunoglobulin A (IgA) vasculitis market share, detailed immunoglobulin A (IgA) vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin A (IgA) vasculitis market. This immunoglobulin A (IgA) vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunoglobulin A (IgA) vasculitis market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to increasing awareness of IgA vasculitis, a rising incidence of autoimmune diseases, greater use of immunosuppressive therapies, increased research funding for rare diseases, and growing adoption of targeted treatment options.

The immunoglobulin A (IgA) vasculitis market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the increasing use of advanced biomarkers, rising incidence of comorbid conditions, a growing number of clinical trials, heightened interest in biologic therapies, and expanding demand for minimally invasive treatment options. Major trends include the integration of precision medicine, innovations in immunosuppressive therapies, development of disease-modifying treatments, advancements in biomarkers for early diagnosis, and the incorporation of artificial intelligence in treatment planning.

The rising incidence of autoimmune diseases is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells, tissues, or organs instead of defending against infections. The increasing prevalence of these disorders is largely attributed to greater exposure to environmental pollutants, which can disrupt immune regulation and trigger abnormal immune responses. IgA vasculitis plays a role in autoimmune diseases by causing inflammation in small blood vessels, providing insights that may aid in understanding and treating various autoimmune conditions. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, corresponding to a raw prevalence rate of 8.61%. Therefore, this rising incidence is propelling the growth of the IgA vasculitis market.

The rising focus on targeted therapies is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Targeted therapies are treatments designed to specifically inhibit molecular abnormalities involved in diseases, thereby improving treatment precision and minimizing damage to healthy cells. This growing emphasis on targeted therapies is largely fueled by advancements in precision medicine, which tailors treatments based on an individual's genetic profile for greater effectiveness. In IgA vasculitis, targeted therapies focus on specific immune pathways, reducing systemic side effects, lowering inflammation, and preventing organ damage-ultimately enhancing patient outcomes and quality of life. For example, in December 2024, the American Society of Gene and Cell Therapy (ASGCT) reported that the FDA approved six gene therapy products in 2023, up from five approvals in 2022, reflecting increased innovation in targeted treatments. Therefore, this rising focus on targeted therapies is propelling the immunoglobulin A vasculitis market forward.

Leading companies in the immunoglobulin A (IgA) vasculitis market are concentrating on creating innovative treatments, including targeted biologics and immunomodulators, aimed at lowering inflammation and preventing kidney-related complications. These advanced therapies work by modulating specific immune pathways to decrease inflammation and protect against immune-driven damage in IgA vasculitis. For example, in April 2025, Novartis AG, a pharmaceutical firm based in Switzerland, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) to treat primary immunoglobulin A nephropathy (IgAN). Vanrafia is a selective endothelin A receptor antagonist taken orally once daily, intended to reduce proteinuria in adults with primary IgAN who face a high risk of rapid disease progression. It can be added to current supportive care plans without requiring a risk evaluation and mitigation strategy (REMS).

Major players in the immunoglobulin A (IgA) vasculitis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Indraprastha Medical Corporation Limited, Intas Pharmaceuticals Ltd, Mayo Clinic, Biogen Inc., Chugai Pharmaceutical Co. Ltd., The Cleveland Clinic Foundation, Zydus Lifesciences Limited, CSL Behring, Artemis Medicare Services Limited, Biocad Biotechnology Company, Biotest AG, Kauvery Hospitals Private Limited, Sheikh Shakhbout Medical City, and Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunoglobulin A (IgA) vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunoglobulin A (IgA) vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunoglobulin A (IgA) vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, renal function monitoring, patient management programs, and clinical research and trials for novel therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunoglobulin A (IgA) vasculitis market also includes sales of corticosteroids, pain relievers, diagnostic kits, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunoglobulin A IgA Vasculitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunoglobulin a iga vasculitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunoglobulin a iga vasculitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunoglobulin a iga vasculitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medications; Plasma Exchange; Supportive Care; Immunosuppressive Therapy
• 2) By Diagnosis Method: Blood Tests; Urinalysis; Imaging Studies; Biopsy
• 3) By Route Of Administration: Oral; Injectables; Intravenous
• 4) By End User: Hospitals; Specialty Clinics; Homecare Settings
• Subsegments:
• 1) By Medications: Corticosteroids; Immunosuppressants; Cyclophosphamide; Azathioprine; Mycophenolate Mofetil
• 2) By Plasma Exchange: Therapeutic Plasma Exchange; Plasma Filtration
• 3) By Supportive Care: Pain Management; Kidney Function Support; Blood Pressure Management
• 4) By Immunosuppressive Therapy: Methotrexate; Rituximab; Cyclophosphamide
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Novartis AG; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immunoglobulin A (IgA) Vasculitis Market Characteristics

3. Immunoglobulin A (IgA) Vasculitis Market Trends And Strategies

4. Immunoglobulin A (IgA) Vasculitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Immunoglobulin A (IgA) Vasculitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immunoglobulin A (IgA) Vasculitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immunoglobulin A (IgA) Vasculitis Market Growth Rate Analysis
• 5.4. Global Immunoglobulin A (IgA) Vasculitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immunoglobulin A (IgA) Vasculitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immunoglobulin A (IgA) Vasculitis Total Addressable Market (TAM)

6. Immunoglobulin A (IgA) Vasculitis Market Segmentation

• 6.1. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Plasma Exchange
• Supportive Care
• Immunosuppressive Therapy
• 6.2. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Urinalysis
• Imaging Studies
• Biopsy
• 6.3. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• Intravenous
• 6.4. Global Immunoglobulin A (IgA) Vasculitis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare Settings
• 6.5. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressants
• Cyclophosphamide
• Azathioprine
• Mycophenolate Mofetil
• 6.6. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Plasma Exchange, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapeutic Plasma Exchange
• Plasma Filtration
• 6.7. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain Management
• Kidney Function Support
• Blood Pressure Management
• 6.8. Global Immunoglobulin A (IgA) Vasculitis Market, Sub-Segmentation Of Immunosuppressive Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methotrexate
• Rituximab
• Cyclophosphamide

7. Immunoglobulin A (IgA) Vasculitis Market Regional And Country Analysis

• 7.1. Global Immunoglobulin A (IgA) Vasculitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immunoglobulin A (IgA) Vasculitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market

• 8.1. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immunoglobulin A (IgA) Vasculitis Market

• 9.1. China Immunoglobulin A (IgA) Vasculitis Market Overview
• 9.2. China Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immunoglobulin A (IgA) Vasculitis Market

• 10.1. India Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immunoglobulin A (IgA) Vasculitis Market

• 11.1. Japan Immunoglobulin A (IgA) Vasculitis Market Overview
• 11.2. Japan Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immunoglobulin A (IgA) Vasculitis Market

• 12.1. Australia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immunoglobulin A (IgA) Vasculitis Market

• 13.1. Indonesia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immunoglobulin A (IgA) Vasculitis Market

• 14.1. South Korea Immunoglobulin A (IgA) Vasculitis Market Overview
• 14.2. South Korea Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immunoglobulin A (IgA) Vasculitis Market

• 15.1. Western Europe Immunoglobulin A (IgA) Vasculitis Market Overview
• 15.2. Western Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immunoglobulin A (IgA) Vasculitis Market

• 16.1. UK Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immunoglobulin A (IgA) Vasculitis Market

• 17.1. Germany Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immunoglobulin A (IgA) Vasculitis Market

• 18.1. France Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immunoglobulin A (IgA) Vasculitis Market

• 19.1. Italy Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immunoglobulin A (IgA) Vasculitis Market

• 20.1. Spain Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market

• 21.1. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market Overview
• 21.2. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immunoglobulin A (IgA) Vasculitis Market

• 22.1. Russia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immunoglobulin A (IgA) Vasculitis Market

• 23.1. North America Immunoglobulin A (IgA) Vasculitis Market Overview
• 23.2. North America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immunoglobulin A (IgA) Vasculitis Market

• 24.1. USA Immunoglobulin A (IgA) Vasculitis Market Overview
• 24.2. USA Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immunoglobulin A (IgA) Vasculitis Market

• 25.1. Canada Immunoglobulin A (IgA) Vasculitis Market Overview
• 25.2. Canada Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immunoglobulin A (IgA) Vasculitis Market

• 26.1. South America Immunoglobulin A (IgA) Vasculitis Market Overview
• 26.2. South America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immunoglobulin A (IgA) Vasculitis Market

• 27.1. Brazil Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immunoglobulin A (IgA) Vasculitis Market

• 28.1. Middle East Immunoglobulin A (IgA) Vasculitis Market Overview
• 28.2. Middle East Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immunoglobulin A (IgA) Vasculitis Market

• 29.1. Africa Immunoglobulin A (IgA) Vasculitis Market Overview
• 29.2. Africa Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immunoglobulin A (IgA) Vasculitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immunoglobulin A (IgA) Vasculitis Market Competitive Landscape And Company Profiles

• 30.1. Immunoglobulin A (IgA) Vasculitis Market Competitive Landscape
• 30.2. Immunoglobulin A (IgA) Vasculitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Immunoglobulin A (IgA) Vasculitis Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Indraprastha Medical Corporation Limited
• 31.3. Intas Pharmaceuticals Ltd
• 31.4. Mayo Clinic
• 31.5. Biogen Inc.
• 31.6. Chugai Pharmaceutical Co. Ltd.
• 31.7. The Cleveland Clinic Foundation
• 31.8. Zydus Lifesciences Limited
• 31.9. CSL Behring
• 31.10. Artemis Medicare Services Limited
• 31.11. Biocad Biotechnology Company
• 31.12. Biotest AG
• 31.13. Kauvery Hospitals Private Limited
• 31.14. Sheikh Shakhbout Medical City
• 31.15. Reliance Life Sciences Pvt. Ltd

32. Global Immunoglobulin A (IgA) Vasculitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immunoglobulin A (IgA) Vasculitis Market

34. Recent Developments In The Immunoglobulin A (IgA) Vasculitis Market

35. Immunoglobulin A (IgA) Vasculitis Market High Potential Countries, Segments and Strategies

• 35.1 Immunoglobulin A (IgA) Vasculitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immunoglobulin A (IgA) Vasculitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immunoglobulin A (IgA) Vasculitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer